DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on February 25, 2008; DOI: 10.1124/dmd.107.018598


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.018598v1
36/5/946    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Donna J Buckley
Arthur R Buckley
Srikanth C Nallani
Pankaj B Desai
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sane, R. S
Right arrow Articles by Desai, P. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sane, R. S
Right arrow Articles by Desai, P. B


Received for publication September 5, 2007.
Revised February 14, 2008.
Accepted for publication February 15, 2008.

Role of human Pregnane X Receptor in tamoxifen and 4-hydroxytamoxifen mediated CYP3A4 induction in primary human hepatocytes and LS174T cells

Rucha S Sane 1, Donna J Buckley 2, Arthur R Buckley 2, Srikanth C Nallani 2, Pankaj B Desai 2*

1 Boehringer Ingelheim Pharmaceuticals Inc 2 University of Cincinnati

* Address correspondence to: E-mail: pankaj.desai{at}uc.edu

Abstract

Previously we observed that the anti-estrogens tamoxifen (tamoxifen) and 4-hyrdoxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell based reporter assays. Given the complex cross-talk between nuclear receptors, tissue-specific expression of CYP3A4 and the potential for tamoxifen and 4OHT to interact with a myriad of receptors, this study was undertaken to gain mechanistic insights into the inductive effects of tamoxifen and 4OHT. Firstly, we observed that transfection of the primary cultures of human hepatocytes with PXR-specific siRNA reduced the PXR mRNA expression and the extent of CYP3A4 induction by tamoxifen and 4OHT by 50%. Secondly, in LS174T colon carcinoma cells, which were observed to have significantly lower PXR expression relative to human hepatocytes, neither tamoxifen nor 4OHT induced CYP3A4. Thirdly, N-desmethyltamoxifen (NDMT), which did not induce CYP3A4 in human hepatocytes, also did not activate PXR in LS174T cells. We then employed cell based reporter assay to evaluate the effects of other receptors such as GR{alpha} and ER{alpha} on the transcriptional activation of PXR. The co-transfection of GR{alpha} in LS174T cells augmented PXR activation by tamoxifen and 4OHT. The presence of ER{alpha} on the other hand, inhibited PXR mediated basal activation of CYP3A4 promoter, possibly via competing for common co-factors such as SRC1 and GRIP1. Collectively, our findings suggest that the CYP3A4 induction by tamoxifen and 4OHT is primarily mediated by PXR but the overall stoichiometry of other nuclear receptors and transcription cofactors also contribute to the extent of the inductive effect.


Key words: anticancer agents, CYP3A, enzyme induction, extrahepatic cytochrome P450, hepatocytes, nuclear receptors, PXR, regulation of gene expression





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.